U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H32O4S
Molecular Weight 416.5755
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SPIRONOLACTONE

SMILES

CC(=O)S[C@]1([H])CC2=CC(=O)CC[C@]2(C)[C@@]3([H])CC[C@@]4(C)[C@@]([H])(CC[C@]54CCC(=O)O5)[C@@]31[H]

InChI

InChIKey=LXMSZDCAJNLERA-ZHYRCANASA-N
InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1

HIDE SMILES / InChI

Molecular Formula C24H32O4S
Molecular Weight 416.5755
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/012151s072lbl.pdf

Spironolactone is a synthetic 17-lactone steroid which is a renal competitive aldosterone antagonist in a class of pharmaceuticals called potassium-sparing diuretics. On its own, spironolactone is only a weak diuretic, but it can be combined with other diuretics. Due to its anti-androgen effect, it can also be used to treat hirsutism, and is a common component in hormone therapy for male-to-female transgendered people. Spironolactone inhibits the effect of aldosterone by competing for intracellular aldosterone receptor in the distal tubule cells. This increases the secretion of water and sodium, while decreasing the excretion of potassium. Spironolactone has a fairly slow onset of action, taking several days to develop and similarly the effect diminishes slowly. Spironolactone is a specific pharmacologic antagonist of aldosterone, acting primarily through competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Spironolactone causes increased amounts of sodium and water to be excreted, while potassium is retained. Spironolactone acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents which act more proximally in the renal tubule. Aldosterone interacts with a cytoplasmic mineralocorticoid receptor to enhance the expression of the Na+, K+-ATPase and the Na+ channel involved in a Na+ K+ transport in the distal tubule . Spironolactone bind to this mineralcorticoid receptor, blocking the actions of aldosterone on gene expression. Aldosterone is a hormone; its primary function is to retain sodium and excrete potassium in the kidneys. Spironolactone is used primarily to treat low-renin hypertension, hypokalemia, and Conn's syndrome.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
11.0 nM [IC50]
120.0 nM [IC50]
650.0 nM [IC50]
1.4 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ALDACTONE

Approved Use

ALDACTONE (spironolactone) is indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. ALDACTONE is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. ALDACTONE is indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension ALDACTONE is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. ALDACTONE is also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy.

Launch Date

-3.13977602E11
Primary
ALDACTONE

Approved Use

ALDACTONE (spironolactone) is indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. ALDACTONE is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. ALDACTONE is indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension ALDACTONE is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. ALDACTONE is also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy.

Launch Date

-3.13977602E11
Primary
ALDACTONE

Approved Use

ALDACTONE (spironolactone) is indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. ALDACTONE is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. ALDACTONE is indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension ALDACTONE is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. ALDACTONE is also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy.

Launch Date

-3.13977602E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
47.4 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SPIRONOLACTONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
150.41 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SPIRONOLACTONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.37 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SPIRONOLACTONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.4 h
unknown
SPIRONOLACTONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
unknown
SPIRONOLACTONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 2 times / day multiple, oral
Studied dose
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
healthy, 21 to 28 years
n = 9
Health Status: healthy
Age Group: 21 to 28 years
Sex: M
Population Size: 9
Sources:
Other AEs: Gynecomastia, Semen abnormal...
Other AEs:
Gynecomastia (66.7%)
Semen abnormal (22.2%)
Sources:
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 33 years
n = 1
Health Status: unhealthy
Condition: Hidradenitis suppurativa
Age Group: 33 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Altered mood, Dizziness...
AEs leading to
discontinuation/dose reduction:
Altered mood
Dizziness
Sources:
25 mg 2 times / day multiple, oral
Recommended
Dose: 25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 25 mg, 2 times / day
Sources:
unhealthy, mean age 45.7 years
n = 18
Health Status: unhealthy
Condition: central serous chorioretinopathy
Age Group: mean age 45.7 years
Sex: M+F
Population Size: 18
Sources:
Disc. AE: Gastric pain, Dizziness...
AEs leading to
discontinuation/dose reduction:
Gastric pain (5.5%)
Dizziness (5.5%)
Arterial hypotension (5.5%)
Sources:
25 mg multiple, oral (median)
Recommended
Dose: 25 mg
Route: oral
Route: multiple
Dose: 25 mg
Sources:
unhealthy, mean age 63 years
n = 1790
Health Status: unhealthy
Condition: hypertension
Age Group: mean age 63 years
Sex: M+F
Population Size: 1790
Sources:
Disc. AE: Gynecomastia, Hyperkalemia...
Other AEs: Gynecomastia, Hyperkalemia...
AEs leading to
discontinuation/dose reduction:
Gynecomastia (2.9%)
Hyperkalemia (1%)
Other AEs:
Gynecomastia (6.4%)
Hyperkalemia (2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Semen abnormal 22.2%
200 mg 2 times / day multiple, oral
Studied dose
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
healthy, 21 to 28 years
n = 9
Health Status: healthy
Age Group: 21 to 28 years
Sex: M
Population Size: 9
Sources:
Gynecomastia 66.7%
200 mg 2 times / day multiple, oral
Studied dose
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
healthy, 21 to 28 years
n = 9
Health Status: healthy
Age Group: 21 to 28 years
Sex: M
Population Size: 9
Sources:
Altered mood Disc. AE
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 33 years
n = 1
Health Status: unhealthy
Condition: Hidradenitis suppurativa
Age Group: 33 years
Sex: F
Population Size: 1
Sources:
Dizziness Disc. AE
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 33 years
n = 1
Health Status: unhealthy
Condition: Hidradenitis suppurativa
Age Group: 33 years
Sex: F
Population Size: 1
Sources:
Arterial hypotension 5.5%
Disc. AE
25 mg 2 times / day multiple, oral
Recommended
Dose: 25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 25 mg, 2 times / day
Sources:
unhealthy, mean age 45.7 years
n = 18
Health Status: unhealthy
Condition: central serous chorioretinopathy
Age Group: mean age 45.7 years
Sex: M+F
Population Size: 18
Sources:
Dizziness 5.5%
Disc. AE
25 mg 2 times / day multiple, oral
Recommended
Dose: 25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 25 mg, 2 times / day
Sources:
unhealthy, mean age 45.7 years
n = 18
Health Status: unhealthy
Condition: central serous chorioretinopathy
Age Group: mean age 45.7 years
Sex: M+F
Population Size: 18
Sources:
Gastric pain 5.5%
Disc. AE
25 mg 2 times / day multiple, oral
Recommended
Dose: 25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 25 mg, 2 times / day
Sources:
unhealthy, mean age 45.7 years
n = 18
Health Status: unhealthy
Condition: central serous chorioretinopathy
Age Group: mean age 45.7 years
Sex: M+F
Population Size: 18
Sources:
Hyperkalemia 1%
Disc. AE
25 mg multiple, oral (median)
Recommended
Dose: 25 mg
Route: oral
Route: multiple
Dose: 25 mg
Sources:
unhealthy, mean age 63 years
n = 1790
Health Status: unhealthy
Condition: hypertension
Age Group: mean age 63 years
Sex: M+F
Population Size: 1790
Sources:
Hyperkalemia 2%
25 mg multiple, oral (median)
Recommended
Dose: 25 mg
Route: oral
Route: multiple
Dose: 25 mg
Sources:
unhealthy, mean age 63 years
n = 1790
Health Status: unhealthy
Condition: hypertension
Age Group: mean age 63 years
Sex: M+F
Population Size: 1790
Sources:
Gynecomastia 2.9%
Disc. AE
25 mg multiple, oral (median)
Recommended
Dose: 25 mg
Route: oral
Route: multiple
Dose: 25 mg
Sources:
unhealthy, mean age 63 years
n = 1790
Health Status: unhealthy
Condition: hypertension
Age Group: mean age 63 years
Sex: M+F
Population Size: 1790
Sources:
Gynecomastia 6.4%
25 mg multiple, oral (median)
Recommended
Dose: 25 mg
Route: oral
Route: multiple
Dose: 25 mg
Sources:
unhealthy, mean age 63 years
n = 1790
Health Status: unhealthy
Condition: hypertension
Age Group: mean age 63 years
Sex: M+F
Population Size: 1790
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Spironolactone-associated aggravation of renal functional impairment.
1976 Mar 10
Pituitary-thyroid function in spironolactone treated hypertensive women.
1979 Apr
Rapid and sensitive reporter gene assays for detection of antiandrogenic and estrogenic effects of environmental chemicals.
1999 Mar 1
[Cosmetics--European Parliament demands marketing prohibition].
2001
[Animal experimentation and animal rights. Evangelical Academy Bad Boll, March 23-25, 2001].
2001
Internet laboratory for predicting harmful effects triggered by drugs and chemicals. Concept and call for co-operation.
2001
[Replacement of the pyrogen-test as batch control test for the biological substances aprotinin and urokinase].
2001
Reconstructed skin equivalents for assessing percutaneous drug absorption from pharmaceutical formulations.
2001
The suitability of hepatocyte culture models to study various aspects of drug metabolism.
2001
A risk-benefit assessment of pharmacological therapies for hirsutism.
2001
[In vitro permeability studies as a substitute for in vivo studies--which requirements have to be met?].
2001
[In vitro models of intestinal and alveolar epithelium cultures in pharmaceutical research].
2001
["Replacement Methods to Animal Testing" as the incentive topic of the German Ministry of Education and Research. Selected results on biological drugs].
2001
[What is the role of hormonal treatments in acne?].
2001 Apr
Aldosteronoma in a dog with polyuria as the leading symptom.
2001 Apr
Population-based investigation of relative clearance of digoxin in Japanese neonates and infants by multiple-trough screen analysis.
2001 Apr
Glucocorticoid and mineralocorticoid receptors are involved in the facilitation of anxiety-like response induced by restraint.
2001 Apr
Factors influencing the prediction of steady state concentrations of digoxin.
2001 Apr
Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications.
2001 Apr
Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.
2001 Apr 15
Reducing readmissions for congestive heart failure.
2001 Apr 15
Effect of a selective aldosterone receptor antagonist in myocardial infarction.
2001 Aug
[Effect of aldosterone on the secretion of endothelin by ventricular fibroblasts].
2001 Feb
Pharmacotherapy of systolic heart failure: emphasis on mortality outcomes.
2001 Feb
K(+) depletion and the progression of hypertensive disease or heart failure. The pathogenic role of diuretic-induced aldosterone secretion.
2001 Feb
Mineralocorticoid receptor-mediated signaling regulates the ion gated sodium channel in vascular endothelial cells and requires an intact cytoskeleton.
2001 Feb 9
Preformulation experiences and in vitro model studies with spironolactone-containing suppositories.
2001 Jan
Laragh's lessons in pathophysiology and clinical pearls for treating hypertension.
2001 Jan
Preventing acute mountain sickness.
2001 Jan
Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites.
2001 Jan
Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management.
2001 Jan
A very short synthesis of steroids from 1,3-butadiene and benzocyclobutenes.
2001 Jan 12
Quality control of inactivated erysipelas vaccines: results of an international collaborative study to establish a new regulatory test.
2001 Jan 8
Genotype/phenotype observations in African Americans with Bartter syndrome.
2001 Jul
Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: role of aldosterone.
2001 Jul
Psychological stress increases hippocampal mineralocorticoid receptor levels: involvement of corticotropin-releasing hormone.
2001 Jul 1
Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes.
2001 Jul 10
Clinical, biochemical and molecular genetic data in five children with Gitelman's syndrome.
2001 Jun
Disappearance of spironolactone-induced gynecomastia with triamteren.
2001 Jun
Determination and characterization of diuretics in human urine by liquid chromatography coupled to pneumatically assisted electrospray ionization mass spectrometry.
2001 Jun
Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure.
2001 Jun 1
High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients.
2001 Mar
Heart biometry and allometry in rats submitted to nitric oxide synthesis blockade and treatment with antihypertensive drugs.
2001 Mar
Long-term efficacy of torsemide compared with frusemide in cirrhotic patients with ascites.
2001 Mar
Breed and heterotic effects on postweaning traits in Altex and New Zealand White straightbred and crossbred rabbits.
2001 May
Effects of canrenone on aorta and right ventricle of the rat.
2001 May
The spironolactone renaissance.
2001 May
Adrenocorticosteroid receptor blockade and excitotoxic challenge regulate adrenocorticosteroid receptor mRNA levels in hippocampus.
2001 May 1
Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.
2001 May 5
Primary aldosteronism: a practical approach to diagnosis and treatment.
2001 May-Jun
Patents

Sample Use Guides

Usual Adult Dose for Edema 25 to 200 mg/day orally in 1 or 2 divided doses. Usual Adult Dose for Hypertension 25 to 200 mg/day orally in 1 or 2 divided doses. Usual Adult Dose for Hypokalemia 25 to 200 mg/day orally in 1 or 2 divided doses. Usual Adult Dose for Primary Hyperaldosteronism Diagnosis 100 to 400 mg/day orally in 1 or 2 divided doses. Usual Adult Dose for Hirsutism 50 to 200 mg/day orally in 1 or 2 divided doses. Usual Adult Dose for Congestive Heart Failure 25 mg/day orally. Increase or decrease based on response and evidence of hyperkalemia. Usual Adult Dose for Primary Hyperaldosteronism Initial dose: 100 mg orally once a day. This dosage may be divided into two daily doses, and increased as tolerated every two to three days to a maximum recommended total daily dose of 400 mg.
Route of Administration: Oral
Spironolactone (10 uM) abrogated MR agonist aldosterone-increased I (CaL) density in adult rat ventricular myocytes
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:55:29 UTC 2021
Edited
by admin
on Fri Jun 25 20:55:29 UTC 2021
Record UNII
27O7W4T232
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SPIRONOLACTONE
EP   HSDB   INCI   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   INCI  
Official Name English
SPIRONOLACTONE [MART.]
Common Name English
VEROSPIRONE
Common Name English
SPIRONOLACTONE [INCI]
Common Name English
17-HYDROXY-7.ALPHA.-MERCAPTO-3-OXO-17.ALPHA.-PREGN-4-ENE-21-CARBOXYLIC ACID, .GAMMA.-LACTONE ACETATE
Common Name English
SPIRONOLACTONE CEVA
Brand Name English
SPIRONOLACTONE [IARC]
Common Name English
ALDACTONE
Brand Name English
SPIRONOLACTONUM [WHO-IP LATIN]
Common Name English
SPIRONOLACTONE [WHO-DD]
Common Name English
SPIRONOLACTONE [JAN]
Common Name English
SPIRONOLACTONE COMPONENT CARDALIS
Common Name English
SPIRONOLACTONE [USP MONOGRAPH]
Common Name English
SPIRONOLACTONE [WHO-IP]
Common Name English
NSC-150399
Code English
CARDALIS COMPONENT SPIRONOLACTONE
Brand Name English
SPIRONOLACTONE [ORANGE BOOK]
Common Name English
SPIRONOLACTONE [USP-RS]
Common Name English
SPIRONOLACTONE [INN]
Common Name English
SPIRONOLACTONE [MI]
Common Name English
SPIRONOLACTONE [EMA EPAR: VETERINARY]
Common Name English
SPIRONOLACTONE [VANDF]
Common Name English
SPIRONOLACTONE COMPONENT OF ALDACTAZIDE
Common Name English
PREGN-4-ENE-21-CARBOXYLIC ACID, 7-(ACETYLTHIO)-17-HYDROXY-3-OXO-,.GAMMA.-LACTONE, (7.ALPHA.,17.ALPHA.)-
Common Name English
ALDACTAZIDE COMPONENT SPIRONOLACTONE
Common Name English
SPIRONOLACTONE [HSDB]
Common Name English
SC-9420
Code English
SPIRONOLACTONE [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-ESSENTIAL MEDICINES LIST 16
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
EMA VETERINARY ASSESSMENT REPORTS SPIRONOLACTONE CEVA [AUTHORIZED]
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
NDF-RT N0000011310
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
FDA ORPHAN DRUG 430614
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
IARC Spironolactone
LIVERTOX 896
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
NCI_THESAURUS C49186
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
WHO-ATC C03DA01
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
NDF-RT N0000175557
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
EMA VETERINARY ASSESSMENT REPORTS CARDALIS (AUTHORISED)
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
WHO-VATC QC03DA01
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
Code System Code Type Description
DRUG CENTRAL
2475
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY
EPA CompTox
52-01-7
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY
CAS
52-01-7
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY
DRUG BANK
DB00421
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY
WIKIPEDIA
SPIRONOLACTONE
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY
LACTMED
Spironolactone
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY
NCI_THESAURUS
C840
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY
PUBCHEM
5833
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY
HSDB
3184
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY
EVMPD
SUB127260
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
ALTERNATIVE
INN
987
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY
MESH
D013148
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
SPIRONOLACTONE
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY Description: A light yellowish white to light yellowish brown powder; odourless or with a faint characteristic odour. Solubility: Practically insoluble in water; soluble in ethanol (~750 g/l) TS. Category: Diuretic. Storage: Spironolactone should be kept in a well-closed container, protected from light. Additional information: Spironolactone may show preliminary melting at about 135?C, followed by resolidification. Definition: Spironolactone contains not less than 97.0% and not more than 101.5% of C24H32O4S, calculated with reference to the dried substance.
EVMPD
SUB10631MIG
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY
ChEMBL
CHEMBL1393
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY
IUPHAR
2875
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-133-6
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY
FDA UNII
27O7W4T232
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY
USP_CATALOG
1619006
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY USP-RS
MERCK INDEX
M10157
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY Merck Index
RXCUI
9997
Created by admin on Fri Jun 25 20:55:29 UTC 2021 , Edited by admin on Fri Jun 25 20:55:29 UTC 2021
PRIMARY RxNorm
Related Record Type Details
BINDER->LIGAND
TARGET->PARTIAL ANTAGONIST
BINDING
TARGET -> INHIBITOR
Is a prodrug that Inhibits through active metabolites.
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
METABOLITE ACTIVE -> PRODRUG
MAJOR
PLASMA
METABOLITE -> PARENT
METABOLITE ACTIVE -> PRODRUG
The pharmacological activity of spironolactone metabolites in man is not known. However, in the adrenalectomized rat the antimineralocorticoid activities of the metabolites C, TMS, and HTMS, relative to spironolactone, were 1.10, 1.28, and 0.32, respectively.
METABOLITE ACTIVE -> PRODRUG
Has in vitro activity
METABOLITE ACTIVE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
correction factor: for the calculation of content, multiply the peak area of impurity F by 2.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC